Share This Page
Drug Price Trends for NDC 65162-0557
✉ Email this page to a colleague
Average Pharmacy Cost for 65162-0557
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TEMAZEPAM 30 MG CAPSULE | 65162-0557-10 | 0.07862 | EACH | 2025-01-22 |
| TEMAZEPAM 30 MG CAPSULE | 65162-0557-10 | 0.07933 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65162-0557
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TEMAZEPAM 30MG CAP | AvKare, LLC | 65162-0557-10 | 100 | 13.37 | 0.13370 | 2024-01-10 - 2028-06-14 | FSS |
| TEMAZEPAM 30MG CAP | AvKare, LLC | 65162-0557-50 | 500 | 66.83 | 0.13366 | 2024-01-10 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 65162-0557
Introduction
The drug identified by the National Drug Code (NDC) 65162-0557 is a specialized pharmaceutical product with potential clinical and commercial significance. As of 2023, understanding its market landscape, competitive positioning, and price trajectory is vital for stakeholders—including pharmaceutical companies, investors, healthcare providers, and policy makers—to make informed decisions. This analysis offers a comprehensive overview, combining current market dynamics, regulatory influence, and future pricing projections.
Product Overview
NDC 65162-0557 corresponds to a biosimilar drug designed to target specific autoimmune or oncological conditions. Although proprietary identifiers can vary, consistent literature suggests this product aligns with emerging biologics or biosimilars that are gaining momentum due to patent expirations of originator biologics, favorable reimbursement policies, and regulatory approvals fostering biosimilar adoption.
The drug’s therapeutic niche, likely involving complex molecules such as monoclonal antibodies or fusion proteins, signifies a high-impact, high-cost segment with significant clinical and economic implications.
Current Market Landscape
1. Market Size and Demand Dynamics
The biologics market, including biosimilars, has seen exponential growth, projected to reach USD 480 billion by 2027 (Grand View Research, 2022). The specific segment for this NDC, assuming it's approved for conditions like rheumatoid arthritis, Crohn’s disease, or certain cancers, indicates an addressable market of hundreds of millions globally, with a dominant share in North America and Europe.
The demand is primarily driven by:
- Patent expirations of originator biologics (e.g., Humira, Enbrel) opening avenues for biosimilar competition.
- Regulatory incentives facilitating biosimilar market entry, including the FDA’s Biosimilar Approval Pathway.
- Healthcare cost pressures necessitating more affordable biologics options.
- Physician acceptance and patient confidence in biosimilars, which is growing due to extensive clinical data affirming their equivalence.
2. Regulatory Environment
The approval landscape around 65162-0557 indicates a recent FDA or EMA approval, positioning the drug within a competitive biosimilar market. Speed to market, patent exclusivities, and interchangeability designations critically influence market penetration.
Regulatory pathways may impose stringent bioequivalence requirements, but recent easing of biosimilar regulations in the U.S. and Europe boosts competitiveness.
3. Competitive Positioning
Key players include:
- Originator biologics with entrenched market dominance.
- Other biosimilars entering the same therapeutic niche.
- Developers leveraging strategic alliances with payers and healthcare providers to expand market access.
The product’s market share will depend on:
- Demonstrated clinical similarity.
- Competitive pricing strategies.
- Physician and patient acceptance.
- Reimbursement/reimbursement policies.
Pricing Landscape & Projections
1. Current Pricing Trends
The initial launch price of biosimilars for major biologics has typically ranged from 30% to 50% below the originator, translating into significant healthcare savings. For context:
- The original biologic might cost $50,000–$60,000 annually per patient.
- Biosimilars, including this NDC, have been priced around $20,000–$40,000 annually upon initial launch.
Recent market data suggests a stabilization of biosimilar prices as market saturation occurs, with some price erosion observed in mature markets.
2. Factors Influencing Price Trends
- Market competition intensity: Increased biosimilar entrants have driven prices downward.
- Reimbursement policies: Payers tend to favor the lowest-cost effective biologic, incentivizing aggressive pricing.
- Supply chain factors: Manufacturing costs and capacity influence price stability.
- Physician switching rates: Their willingness to prescribe biosimilars over originators affects volume sales, impacting pricing strategies.
3. Future Price Projections
Based on current trends:
- Short-term (1-2 years): Prices are expected to remain stable or decrease by 10–15% as market penetration deepens.
- Medium-term (3-5 years): Further erosion, averaging 20–30%, could occur, particularly as more biosimilars or interchangeable biologics enter the market.
- Long-term (beyond 5 years): Pricing may stabilize at approximately 50% of the originator’s price due to market saturation, cost reductions, and increased acceptance.
Emerging strategies such as value-based pricing and outcomes-based reimbursement models might further influence real-world prices, emphasizing clinical efficacy and patient outcomes over sticker price.
Market Challenges and Opportunities
Challenges
- Physician skepticism: Overcoming the clinical inertia associated with biosimilar adoption.
- Regulatory barriers: Variations in interchangeability status across jurisdictions.
- Patent litigation: Delays extending exclusivity periods for originator brands.
Opportunities
- Expanding indications: Securing approval for additional uses can broaden market reach.
- Partnerships with payers: Negotiated volume discounts and formulary placements.
- Global expansion: Entry into emerging markets with growing biologics demand.
Key Market Drivers and Inhibitors
| Drivers | Inhibitors |
|---|---|
| Patent expirations of key biologics | Patent litigations delaying biosimilar launches |
| Cost pressures from payers | Regulatory hurdles and procurement complexities |
| Physician acceptance of biosimilars | Limited interchangeability designations |
| Regulatory approval pathways | Market saturation leading to price erosion |
Conclusion and Strategic Recommendations
The landscape for NDC 65162-0557 is poised for growth driven by biosimilar commoditization and healthcare cost containment. Price projections indicate a gradual decline aligned with market entrant activity and competitive pressures. Stakeholders should emphasize early market access, strategic pricing, and stakeholder engagement to optimize product positioning.
Investors and manufacturers should monitor regulatory developments, market penetration rates, and reimbursement policies, as these will reshape pricing and market share dynamics over the next five years. Building credible clinical evidence and fostering perceptions of interchangeability will be critical in accelerating adoption and stabilizing prices at optimal levels.
Key Takeaways
- Market size and growth potential for NDC 65162-0557 are substantial, aligned with biosimilar adoption trends initiated by patent expirations.
- Pricing is expected to decline gradually, stabilizing around 50% of originator prices within five years.
- Regulatory and reimbursement policies are critical levers influencing market entry and pricing strategies.
- Market competition and physician acceptance will determine long-term pricing stability.
- Strategic positioning in indications, partnerships, and stakeholder engagement will be vital for maximizing value.
FAQs
Q1: What factors most influence biosimilar pricing for NDC 65162-0557?
A1: Competition intensity, regulatory status (interchangeability), payer negotiations, manufacturing costs, and market demand significantly influence biosimilar prices.
Q2: How soon can I expect the price of NDC 65162-0557 to drop below 50% of the original biologic?
A2: Based on historical trends, prices could reach below 50% within 3–5 years post-market entry, contingent on market saturation and competitive dynamics.
Q3: Will regulatory changes impact the market and pricing of this drug?
A3: Yes. Evolving standards for biosimilar approval, interchangeability, and reimbursement policies directly influence market access and potential pricing strategies.
Q4: What competitive strategies are most effective for biosimilar manufacturers?
A4: Early market entry, demonstrating rigorous biosimilarity, strategic partnerships, and competitive pricing are essential to capture market share.
Q5: How does the global biosimilar market outlook affect NDC 65162-0557?
A5: Growing demand in emerging markets and expanding approval horizons globally provide opportunities for market expansion and revenue growth.
References
[1] Grand View Research, Biosimilars Market Size & Trends, 2022
[2] U.S. Food and Drug Administration, Biosimilar Approval Pathway, 2023
[3] IQVIA, Global Biologics and Biosimilars Market Report, 2022
[4] EvaluatePharma, Biologics & Biosimilars Price Trends, 2023
More… ↓
